ASCO 2021 – Peter R. Galle

Peter R. Galle overviews the role of immunotherapy in the setting of hepatocellular carcinoma as well as biomarker-based patient selection and discusses which novel combinations of immune checkpoint inhibitors with other drug classes are most promising at present and how those novel strategies impact the treatment landscape.

Here is the full ASCO 2021 report.

More posts